

## GLAXOSMITHKLINE ORD GBP0.25

ISIN: **GB0009252882** WKN: **0925288**

## Overview

2021/04/09 17:42:54

Price  
18.05 USDDifference  0.33% (0.06)

## General attributes

ISIN	GB0009252882
Symbol	GSK
Exchange	FINRA other OTC Issues
Currency	USD
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	75,954 EUR
Benchmark	FTSE 100

## Market data

Bid (Bid size)	-
Ask (Ask size)	-
Open	18.05 USD
High	18.05 USD
Low	18.05 USD
Close (prev. day)	17.99 USD
VWAP	18.05 USD
Volume (pcs)	624
Trading volume	11,267.87
Number of trades	6
Last size	500

## Futures and Options

Related Futures	42
Related Options	-

## PDF Downloads






Annual report: GLAXOSMITHKLINE ORD GBP0.25 

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Recent research

on instrument		on sector	
Date		Headline	Download
2021/04/08		Global Equity Ratings	
2021/04/08		Aktienempfehlungen Global	
2021/04/01		Global Equity Ratings	
2021/04/01		Aktienempfehlungen Global	
2021/03/03		Global Equity Ratings	

## Details

2021/04/09 17:42:54

## Price

18.05 USD

Difference ▲ 0.33% (0.06)

## General attributes

ISIN GB0009252882

Symbol GSK

Exchange FINRA other OTC Issues

Currency USD

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 75,954 EUR

Benchmark FTSE 100

## Market data

Bid (Bid size) -

Ask (Ask size) -

Open 18.05 USD

High 18.05 USD

Low 18.05 USD

Close (prev. day) 17.99 USD

VWAP 18.05 USD

Volume (pcs) 624

Trading volume 11,267.87

Number of trades 6

Last size 500

## Performance and Risk

	6M	1Y	3Y
Perf (%)	-2.38%	-5.99%	-9.07%
Perf (abs.)	-0.44	-1.15	-1.80
Beta	0.80	0.69	0.69
Volatility	32.65	39.35	36.39

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Price data

Ø price 5 days   Ø volume 5 days (pcs.)	17.97 USD (3,172)
Ø price 30 days   Ø volume 30 days (pcs.)	17.55 USD (346,009)
Ø price 100 days   Ø volume 100 days (pcs.)	18.08 USD (412,970)
Ø price 250 days   Ø volume 250 days (pcs.)	18.90 USD (168,231)
YTD High   date	19.73 USD (2021/01/26)
YTD Low   date	16.50 USD (2021/02/05)
52 Weeks High   date	22.00 USD (2020/04/27)
52 Weeks Low   date	16.50 USD (2021/02/05)

## Arbitrage views

Exchange <span style="color: blue;">⊕</span>	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2021/04/09	17:35	15.46 EUR	1.94	212
Tradegate	2021/04/09	22:26	15.56 EUR	1.04	155
Stuttgart	2021/04/09	21:52	15.58 EUR	0.04	12
SIX Swiss Exchange	2020/04/21	17:36	21.50 CHF	0.00	1
Munich	2021/04/09	10:49	15.34 EUR	0.00	2

	09					
London Stock Exchange	2021/04/09	17:35	1,319.60 GBp	8,439.35		11,705
Hanover	2021/04/09	08:04	15.36 EUR	0.00		2
Hamburg	2021/04/09	10:31	15.32 EUR	0.00		2
Frankfurt	2021/04/09	16:37	15.36 EUR	0.05		7
FINRA other OTC Issues	2021/04/09	17:42	18.05 USD	0.01		6
Duesseldorf	2021/04/09	19:30	15.42 EUR	0.00		22
Berlin	2021/04/09	15:03	15.36 EUR	0.00		2

## Company profile

### Company Logo



### Contact Details

GLAXOSMITHKLINE PLC

--

980 Great West Road - TW8 9GS Middlesex

Telefon: 44-20-8047-5000

Fax: 44-20-8047-7807

E-mail: -

### PDF Downloads

Annual report: GLAXOSMITHKLINE  
ORD GBP0.25

### Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

### Members of Management Board

Emma Walmsley	Chairman of Managing Board
Christopher Corsico	Member of Executive Committee
Jon Ellis	Member of Executive Committee
Lon Cardon	Member of Executive Committee
Neil Barnes	Member of Executive Committee
Rab Prinjha	Member of Executive Committee
Amy Altshul	Member of Executive Committee
Brian McNamara	Member of Executive Committee
David Redfern	Member of Executive Committee
Deborah Waterhouse	Member of Executive Committee
Diana Conrad	Member of Executive Committee
James Ford	Member of Executive Committee
Karenann Terrell	Member of Executive

### Board of directors

Jonathan Symonds	Chairman of Supervisory Board
Hal Barron	Member of Supervisory Board
Jesse Goodman	Member of Supervisory Board
Laurie Glimcher	Member of Supervisory Board
Charles Bancroft	Member of Supervisory Board
Iain Mackay	Member of Supervisory Board
Judy Lewent	Member of Supervisory Board
Lynn Elsenhans	Member of Supervisory Board
Manvinder Singh Banga	Member of Supervisory Board
Urs Rohner	Member of Supervisory Board
Vivienne Cox	Member of Supervisory Board

	Committee
Kevin Sin	Member of Executive Committee
Luke Miels	Member of Executive Committee
Marc Jones	Member of Executive Committee
María Cristina Henríquez de Luna Basagoiti	Member of Executive Committee
Maya Martinez-Davis	Member of Executive Committee
Nick Hirons	Member of Executive Committee
Philip Thomson	Member of Executive Committee